Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Jan 18;11:534111. doi: 10.3389/fphar.2020.534111

Grindelia squarrosa Extract and Grindelic Acid Modulate Pro-inflammatory Functions of Respiratory Epithelium and Human Macrophages

Barbara Gierlikowska 1,*, Agnieszka Filipek 2, Wojciech Gierlikowski 3, Dominika Kania 2, Joanna Stefańska 4, Urszula Demkow 1, Anna K Kiss 2
PMCID: PMC7848105  PMID: 33536899

Abstract

Aim of the study: Both nasal and bronchial epithelial cells have evolved sophisticated mechanisms involved in cellular response to bacterial infection. Recognition of pathogens by TLR receptors activate the NF-κB transcription factor, and lead to production of wide spectrum of cytokines (TNF-α, IL-1β, IL-6 and IL-8). Released by epithelium proinflammatory cytokines intensify migration of macrophages to damaged tissues and modulate their pro-inflammatory functions. Based on traditional use of G. squarrosa aerial parts we hypothesized that successful treatment of cold-related diseases may arise from modulation of the pro-inflammatory functions of respiratory epithelium and human monocytes/macrophages. The biological activity of G. squarrosa extract and grindelic acid were compared with clarithromycin and budesonide used as positive controls.

Methods: The expression of surface receptors (TLR-4, IL-10) and expression of adhesive molecules (ICAM-1, VCAM-1, E-selectin) was analyzed with flow cytometry. The macrophage attachment to the epithelial cells was assessed fluorimetrically. The p65 NF-κB concentration and cytokine production was measured spectrophotometrically using enzyme-linked immunosorbent assay. Antibacterial activity was examined by the standard disc-diffusion method and serial dilution method according to CLSI guidelines.

Results: G. squarrosa extract and grindelic acid had no antimicrobial effect. However, we noticed significant modulation of pro-inflammatory functions of LPS-stimulated nasal and bronchial epithelium. G. squarrosa extract treatment resulted in decrease of TLR-4 expression and p65 NF-κB concentration and inhibition of cytokines synthesis (IL-8, TNF-α, IL-1β and IL-6) in both cellular models. Additionally, G. squarrosa extract slightly modulated ICAM-1 expression affecting on attachment of macrophages to epithelium. Only G. squarrosa extract was able to stimulate the anti-inflammatory functions of macrophages by inducing TGF-β release and IL-10 receptor surface expression. Grindelic acid, identified as a dominant compound in the plant extract, modulated pro-inflammatory functions of epithelium and macrophages slightly.

Conclusion: The obtained results support traditional use of Grindelia squarrosa preparations for a treatment cold-associated diseases symptoms. In our opinion, the observed biological effect of extract may be a consequence of synergistic effect of all compounds present in the extract.

Keywords: Grindelia squarrosa, grindelic acid, inflammation, cold syndrome, respiratory epithelium, macrophages

Introduction

Common cold is one of the most common occurring acute illnesses in humans. In a large-scale survey, 25% of all those questioned in the United Kingdom had suffered from 3 to 6 colds during the previous year and 73% reported having a common cold at least once during this period. The similar tendency is observed in Germany and United States. The acute episode of a cold is starting with viral infection and may be accompanied by bacterial superinfection. The most common bacterial isolates from people with cold syndromes include Gram-positive strains, such as Streptococcus pneumoniae responsible for pharyngitis, bronchitis or pneumonia (Klugman and Feldman, 2001); Staphylococcus aureus responsible for pharyngitis and epiglottitis, Hemophilus influenzae, which occupy a similar microenvironment within the nasopharynx as Streptococcus pneumoniae (Erwin and Smith, 2007), and other opportunistic organisms as Escherichia coli (Mizgerd, 2008).

Common cold treatment is mostly directed towards relief of symptoms. The infection results in development of full-symptomatic inflammation and overproduction of cytokines. Currently accepted cold treatment strategies focus on suppression of inflammation by anti-inflammatory drugs. Treatment may be enhanced by inclusion of antibiotic therapy. However, using antibiotics bring benefits only for the treatment of secondary bacterial infections. The valuable approach in the cold treatment may be strengthen immune system in order to prevent the uncontrolled progression of inflammation, but also protection of the respiratory epithelium against excessive damage.

Because airway epithelial cells are a border line between external and internal environment, they are particularly vulnerable to damage. Epithelial cells express a wide spectrum of receptors, such as Toll-like receptors. TLRs identify pathogen-associated molecular patterns (PAMPs), and initiate the appropriate cellular response. Among known TLRs, TLR-4 is the main LPS receptor (Zusso et al., 2019). Binding the LPS results in the activation of downstream mediators, including the transcription factor nuclear factor NF-κB, which stimulates the production of pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) (Spiegler et al., 2020). Released cytokines intensify migration of macrophages to the site of infection. The released cytokines modulate adhesion molecules expression (ICAM-1, VCAM-1 and E-selectin) on the respiratory epithelium, thus mediate direct emigration of macrophages across the endothelial and epithelial barriers that separate the bloodstream from the pulmonary air spaces (Martin et al., 1992; Martin, 2000; Puneet et al., 2005). The infiltrated macrophages are activated and released wide spectrum of inflammatory mediators: reactive oxygen species (ROS), cytokines (TNF-α, IL-6, TGF-β), and modulate expression of membrane receptors such as IL-10 (Michalak et al., 2018).

According to World Health Organization (WHO) guidelines, over 90% of the population of developed and developing countries, uses the wealth of phytomedicine. Grindelia squarrosa well-known in South America, Asia and Europe is still sold as complex preparations (liquid extracts, syrups) for treating cough and bronchitis (Strzelecka, 2000). According to European Medicines Agency (EMA) there are various types of preparations: tincture or herbal tea (Table 1). The toxicity of this plant to humans is negligible, what intensified the traditional use of the herb (Goetz, 2005).

TABLE 1.

The forms of G. squarrosa extract administration.

Form Administration Part References
Infusion 3 g in 150 ml of boiling water. Daily dose: up to 3 times daily Aerial parts, flowers, leaves Kalktenbach and Schimmer (1991), Ferreres et al. (2014)
Tincture 0.5–1 ml 3 times daily. Daily dose: 1.5–3 ml Aerial parts, flowers Kalktenbach and Schimmer (1991)
Liquid extract 0.6–1.2 ml 3 times daily. Daily dose: 1.8–3.6 ml Aerial parts, flowers, leaves Kalktenbach and Schimmer (1991), McFarlane (2017)
Open in a new tab

The Grindelia is valuable source of biologically active compounds (Capasso et al., 2003). The aerial parts of G. squarrosa are a rich source of diterpenes. It contains grindelic, 6-oxygrindelic, 18-hydroxy-6-oxygrindelic, 7-alpha-oxodihydrogrindelic and 8-alpha-oxodihydrogrindelic acids. As dominant diterpene was identified grindelic acid, which may consist of 20–60% of grindelia resin and up to 6% of dry plant material (Johnson, 1887; Efferth and Koch, 2011; Nowak and Rychlińska, 2012; Veres et al., 2014). The plant also contains flavonoids, phenolic acids, an essential oils, polyacetylenes and saponins (Veres et al., 2014).

Although G. squarrosa extracts are present at pharmaceutical market, there is still lack of studies fully explaining their anti-microbial and anti-inflammatory properties. In present study, we have evaluated influence of Grindelia squarrosa extract on pro-inflammatory functions of LPS-stimulated nasal and bronchial epithelial cells and macrophages. We highlight new anti-inflammatory properties of the extract, and explain how G. squarrsa extract modulates the epithelium response to LPS.

Materials and Methods

Chemicals

Normal Human Bronchial Epithelial Cells (NHBE) and Bronchial Epithelial Cell Growth Medium were obtained from Lonza (Switzerland). Primary Human Nasal Epithelial Cells (HNEpC) and Airway Epithelial Cell Growth Medium were obtained from Promocell (Germany). Grindelic acid (purity ≥95% (LC/MS-ELSD)), clarithromycin (purity ≥95% (HPLC)), budesonide (purity ≥98% (HPLC)), LPS (from Escherichia coli 0,111:B4), Ficoll Hypaque gradient, GM-CSF, HEPES buffer, l-glutamine, RPMI 1640 medium, Fetal bovine serum (FBS), Cell Dissociation Solution (non-enzymatic), Accutase™, propidium iodide and Calcein-AM were purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). TLR-4-(PE)-conjugate (cat no. HTA125) was obtained from eBioscience. Human Quantikine ELISA Kits were purchased from R&D System (Minneapolis, USA). Anti-Human CD54-(-APC) (cat no. 559771), Anti-Human CD106-(-PE) (cat no. 555647), Anti-Human CD62E-(-PE) (cat no. 551145) were purchased from BD Pharmingen.

Plant Material and Phytochemical Analysis

The plant material Grindelia squarrosa (Pursh) Dunal (http://www.theplantlist.org/tpl1.1/record/gcc-87994) was collected in July 2018 in Lublin Medicinal Plant Garden, Department of Pharmacognosy with Medicinal Plant Unit, Medical University of Lublin (51°15′22″N, 22°33′51″E) were the voucher specimen is deposited (27a/13).

The air-dried plant material (5 g) was extracted with 60% ethanol (v/v, 1:10) in a water bath (70 °C) for 1 h three times. Then, combined extracts were filtered, the ethanol was evaporated, and the water residue was lyophilized. The phytochemical characterization was performed using UHPLC-DAD-ESI-MSn analysis (UHPLC-3000 RS system, Dionex, Germany) with DAD detection and an AmaZon SL ion trap mass spectrometer with an ESI interface (Bruker Daltonik GmbH, Bremen, Germany). Separation was performed on a Zorbax SB-C18 column (150 × 2.1 mm, 1.9 μm) (Agilent, Santa Clara, CA, United States). The mobile phase consisted of 0.1% HCOOH in water (A) and 0.1% HCOOH in MeCN (B) using the following gradient: 0–60 min 5–100% B. The LC eluate was introduced into the ESI interface and compounds were analyzed in negative ion mode (for phenolic acids and flavonoids) and with positive ion mode (for diterpenes) with the following settings: nebulizer pressure of 40 psi; drying gas flow rate of 9 L/min; nitrogen gas temperature of 300 °C; and a capillary voltage of 4.5 kV. The mass scan ranged from 100 to 2,200 m/z. UV spectra were recorded in the range of 190–350 nm. The characterization of substances in the extract was performed by comparing the retention times and spectra (UV, MS, MSn) with published data.

Isolation of grindelic acid (GA). The plant material (50 g) was extracted three times with 60% ethanol (1:20) at 70 °C for 2 h each time. The ethanol from combined extracts was evaporated under reduced pressure, and the aqueous residue was then extracted four times with ethyl acetate (150 ml). The ethyl acetate residue (5.2 g) was subjected to Sephadex LH-20 column chromatography (80 × 2.5 cm) and eluted 70% MeOH to obtain four main fractions of 0.236 g (F1), 0.805 g (F2), 1.062 g (F3) and 0.480 g (F4), respectively. Fraction F4, containing GA, based on TLC analysis with comparison with standard, was separated on a Silica gel column (55 × 2.5 cm; 100–200 μm) with CHCL3-MeOH gradient (100:0 → 90:10) in seven steps. Ten fractions of 25 ml each were pooled into six main fractions (F4_1-F4_6) based on their TLC profiles. From fraction F4_1 (0.22 g) GA (152 mg), was isolated using Silica gel column (55 × 2.5 cm; 0.63 μm) and CHCL3 as eluent. The structure of GA was confirmed by their 1H and 13C NMR spectra, which were compared with reference data (Reta et al., 2013).

Preparation of Solutions of Extract and Compounds for Bioassays

For all experiments G. squarrosa extract and isolated grindelic acid were used as described above. Extract was dissolved in DMSO (10 mg/ml stock solution) and tested at a concentration range 25–100 µL. Grindelic acid was dissolved in DMSO (10 mM stock solution) and tested at a concentration range of 10–50 µM. The final concentration of DMSO was adjusted to 0.1% (v/v) in culture media.

Antimicrobial Properties of G. squarrosa Extract and Grindelic Acid

Both Gram-positive (Streptococcus pneumoniae ATCC 49619 and Staphylococcus aureus ATCC 25923 ATCC 29213) and Gram-negative (Haemophilus influenzae ATCC 49247) bacteria strains were tested in this study.

Sensitivity of selected bacteria strains was examined by the standard disc-diffusion method according to CLSI (previously NCCLS) guidelines (Watts, 2008). The results (diameter of the growth inhibition zone) were read after 18 h of incubation at 35 °C. Minimal Inhibitory Concentrations (MIC) were evaluated by the two fold serial microdilution method (in 96-well microtiter plates) using Mueller-Hinton Broth medium (Beckton Dickinson) according to CLSI guidelines (Bandi and Kompella, 2001; Watts, 2008).

Primary Human Nasal Epithelial Cells (HNEpC) Culture and Stimulation

HNEpC cells (passage fourth to sixth), were seeded on 12-well plates, 1.5 × 105 cells per well in Airway Epithelial Cell Growth Medium supplemented with 6% Fetal Bovine Serum. The confluent cells were treated with extracts/compounds and then used for experiments.

Normal Human Bronchial Epithelial (NHBE) Culture and Stimulation

NHBE cells (passage fourth to sixth), were seeded on 12-well plates, 1 × 105 cells per well in Bronchial Epithelial Cell Growth Medium. The confluent cells were treated with extracts/compounds and then used for experiments.

Isolation of Human Monocytes and Stimulation

Monocytes were isolated immediately after collection using a Ficoll Hypaque gradient (Dudek et al., 2017). The mononuclear cell band was removed by aspiration, and cells were suspended in RPMI 1640 medium with 2 mM l-glutamine, 10 mM HEPES, antibiotics and autologous serum (5%). To promote the adherence of monocytes/macrophages, the peripheral blood mononuclear cell suspension was placed in 12-well tissue culture plates (2 × 106 per well) and incubated for 2 h at 37 °C under humidified 5% CO2 air. After the incubation, nonadherent cells were removed, and adherent cells were cultured with RPMI 1640 medium supplemented with heat-inactivated fetal bovine serum (FBS, 10%) and granulocyte macrophage-colony stimulating factor (GM-CSF, 10 ng/ml) for 7 days to induce differentiation to macrophages. The medium and autologous serum were replaced every 2 days.

Determination of Cytotoxicity by PI-Staining

Cytotoxicity of the tested extract and compounds was determined by PI-staining. Cells were treated with the compounds for 24 h, centrifuged (1,500 RPM; 5 min; 4 °C) and re-suspended in 300 µL of PBS. 5 µL of PI (50 μg/ml) solution was added to the cell suspensions and incubated 10 min in the dark. Cytotoxic effects of the extract and compounds were measured by BD FACS LSR Fortessa flow cytometer (BD Biosciences, San Jose, CA, United States) by recording 10,000 events per sample and analyzed with FlowJo V10 software. Cells that displayed high permeability to PI were expressed as percentage of PI(+) cells.

Expression of TLR-4 Receptor on Nasal and Bronchial Epithelium

Influence of the tested extract and compounds on the TLR-4 receptor expression was determined by flow cytometry measurement. After 1 h extract- or compounds pretreatment cells were stimulated with LPS for 15 min, and centrifuged (1500 RPM; 10 min; 4 °C). After removing supernatants, cells were re-suspended in 300 μL PBS and labelled with monoclonal antibodies against TLR-4 (eBioscience, United States). The TLR-4 expression was measured by BD FACS LSR Fortessa flow cytometer (BD Biosciences, San Jose, CA, United States) by recording 10,000 cells per sample and analyzed with FlowJo V10 software.

TNF-α, IL-1β, IL-6 and IL-8 Production

Epithelial cells were pretreated with the G. squarrosa extract (at concentration range 25–100 μg/ml) or grindelic acid (at 10–50 μM) for 1 h at 37 °C, and then they were stimulated with LPS (1 μg/ml) for 24 h. Afterwards, cells were centrifuged (1500 RPM; 10 min; 4 °C) and collected supernatants. The total amount of released cytokines was measured by enzyme-linked immunosorbent assay (ELISA) following the manufacturer’s instructions (BD Biosciences, United States). The results were expressed as percentages of the released agents from samples compared to the LPS-stimulated control.

p65 NF-κB Concentration in Nasal and Bronchial Epithelium

Epithelial cells were pretreated with the G. squarrosa extract (at concentration range 25–100 μg/ml) or grindelic acid (at 10–50 μM) for 40 min at 37 °C, and then they were stimulated with LPS (1 μg/ml) for 20 min. The protein isolation was provided as we describe previously (Gierlikowska et al., 2020b). Cells were washed with ice-cold PBS, suspended in hypotonic buffer (5 mM NaF, 0.1 mM EDTA, 20 mM HEPES, 10 µM Na2MoO4), and then centrifuged. The nuclear pellets were lysed with freshly-prepared buffer supplemented with protease inhibitor cocktail and left on ice for 30 min. Pellets were centrifuged for 15 min 2.500 RPM and kept at −80 °C for further analysis.

The protein concentration was measured with Bradford-based method following manufacturer’s protocol. 10 µg of nuclear fraction was transferred on 96-well plate provided by manufacturer. Then, primary antibody (1:1,000 dilution) was added on plate for 1 h, then washed 3 times and incubated with HRP-conjugated secondary antibody (1:1,000 dilution) for additional 1 h. After incubation, plate was washed 3 times and reaction was stopped by adding developing solution and stop solution, respectively. The concentration of NF-κB p65 was measured spectrophotometrically at 450 nm.

Expression of ICAM, VCAM and E-Selectin on Respiratory Surface

Cells were pre-incubated with extract or compounds for 1 h and then stimulated with LPS (1,000 ng/ml, for 24 h). Cell monolayers were washed with PBS and suspended in 200 μL of accutase. After 10 min incubation at 37 °C, the cells were harvested, centrifuged (1500 RPM; 10 min; 4 °C) and suspended in 300 µL of PBS. Cells were labelled with 5 μL of anti-human CD54 (ICAM-1), anti-human CD106 (VCAM-1) or anti-human CD62E (E-selectin).

The expression of adhesive molecules was analyzed by BD FACS LSR Fortessa flow cytometer (BD Biosciences, San Jose, CA, United States) by recording 10,000 cells per sample and analyzed with FlowJo V10 software. The effect on the surface expression of adhesion molecules was evaluated based on a software-generated marker histogram M1 for LPS stimulated cells.

The Attachment of Macrophages to Epithelial Cells

Epithelial cells were pretreated with extract or compounds for 1 h and then stimulated with LPS (1,000 ng/ml, for 24 h). Cell monolayers were washed, suspended in 200 μL of RPMI 1640 medium and added 100 μL of 1 mM calcein-AM labelled macrophages (1×106) as described previously (Michalak et al., 2018). Before calcein labelling, macrophages were stimulated with LPS (100 ng/ml) for an 30 min, and then incubated with epithelial cells for additional 30 min. The cell monolayers with attached macrophages were lysed with 0.1% Triton X-100, and fluorescence was measured in a microplate reader at 485 nm excitation and 520 nm emission.

Expression of IL-10 Receptor on the Macrophage Surface

Macrophages were stimulated with LPS (100 ng/ml for 1 h) and treated with the extract or compounds for 24 h. Subsequently, cells were centrifuged (13,000 RPM, 4 °C, 1 min), suspended in 300 μL of PBS and labelled with antibodies against IL-10. The IL-10 expression was measured by BD FACS LSR flow cytometer (BD Biosciences, San Jose, CA, United States) by recording 10,000 cells per sample and analyzed with CellQuest Pro software. The results were expressed as percentages of cells expressing IL-10 receptor in comparison to control cells stimulated by LPS.

TGF-β, IL-6 and TNF-α Production by Macrophages

Macrophages were cultured in 12-well plates in the presence of LPS (100 ng/ml, 1 h) and then treated with tested extracts/compounds for 24 h at 37 °C with 5% CO2. After 24 h, cells were harvested and centrifuged (2,000 RPM; 10 min; 4 °C). The amounts of released cytokines were measured by ELISA following the manufacturer’s instructions (BD Biosciences, United States). The effect on cytokine production was calculated by comparing the percentages of the released agent to the control cells, which were stimulated but were not exposed to the test compounds.

Statistical Analysis

The results were expressed as the mean ± SEM from three independent experiments assayed in triplicates. All analyses were performed using Statistica 13.1 software. GraphPad Prism (version 5.01) was used to plot data. The statistical significance of the differences between means was established by ANOVA with Dunnett’s post hoc test. p values below 0.05 were considered statistically significant.

Results

G. squarrosa Extract Phytochemical Characterization and Grindelic Acid Isolation

The phytochemical analysis of G. squarrosa extract was performed using a UHPLC-DAD-ESI-MSn method. We confirmed the presence of polyphenolic compounds which are characteristic for Astearaceae family such as caffeoyl quinic acid and dicaffeoyl quinic acids, as well as luteolin and apigenin derivatives (Figure 1; Table 2). As for Grindelia genus the presence of diterpenes is distinctive, we were focused on this group of compounds. However, as grindelic acid do not possess chromophore groups, its detection based on UHPLC-DAD-ESI-MSn was less sensitive. In order to confirm the presence of grindelic acid, we isolated this compound from the extract using ethyl acetate partition and column chromatography (Supplementary Figure S1). We confirmed the purity and structure of isolated GA using NMR spectroscopy (Supplementary Figure S2).

FIGURE 1.

FIGURE 1

Open in a new tab

UHPLC-DAD chromatograms of extract from Grindelia squarrosa at 220 nm (orange line), 254 nm (blue line) and 325 nm (green line).

TABLE 2.

Retention time, UV and MS data of the compounds present in extract from Grindelia squarrosa.

Compound Retention time [min] UV [nm] [M-H]−m/z Fragment ion(s) References
1 Caffeoyl quinic acid 4.0 325 353 191 Ferreres et al. (2014)
2 Feruloyl quinic acid 7.9 325 367 193 Ferreres et al. (2014)
3 Luteolin hexurosyl-pentoside 9.8 330 593 461, 417, 285 Ferreres et al. (2014)
4 Luteolin hexuronide 12.5 334 461 461, 285 Ferreres et al. (2014)
5 Apigenin hexurosyl-pentoside 12.9 334 577 445, 269 Ferreres et al. (2014)
6 Dicaffeoyl quinic acid (I) 14.0 325 515 353, 191, 179, 173 Ferreres et al. (2014)
7 Dicaffeoyl quinic acid (II) 14.9 325 515 353, 191, 179 Ferreres et al. (2014)
8 Dicaffeoyl quinic acid (III) 16.1 325 515 353, 191, 179, 173, 135 Ferreres et al. (2014)
9 6-Oxogrindelic acid 46.0 230 335 a 321 a Mahmoud et al. (2000)
10 Grindelic acid b 50.1 220 321 a 303 a Timmermann et al. (1985)
Open in a new tab
a

[M + H]+;

b

isolated in this study.

G. squarrosa Extract and Grindelic Acid did Not Show Anti-microbial Activity

The G. squarrosa extract (tested at 25–100 μg/ml) and grindelic acid (10–50 µM) did not inhibit bacteria growth. We were not able to detect growth inhibition zone (GIZ, mm) and minimal inhibitory concentration (MIC, μg/mL). The growth inhibition zone was observed only for gram g-positive (S. pneumoniae and S. aureus) treated with clarithromycin. Obtained results were comparable with reference values present at EUCAST (The European Committee on Antimicrobial Susceptibility Testing) (Bandi and Kompella, 2001).

G. squarrosa Extract Decrease the TLR-4 Expression

Stimulation with LPS resulted in a significant increase of TLR-4 expression (Figure 2). Incubation of LPS-stimulated nasal and bronchial epithelial cells with G. squarrosa extract resulted in reduction of TLR-4 expression in the presence of all tested concentrations. The obtained results were comparable to budesonide, tested at 50 µM. Budesonide suppressed the TLR-4 expression on nasal epithelial cells to 63.2% and to 48.5% on bronchial epithelial cells (p < 0.001). Clarithromycin, as well as grindelic acid affect TLR-4 expression slightly. The tested concentrations, did not damage the cellular membrane integrity of nasal and bronchial epithelial cells as presented in Supplementary Table S1 and Figure S3.

FIGURE 2.

FIGURE 2

Open in a new tab

Effects of G . squarrosa extract and compounds on the TLR-4 expression on the LPS-stimulated: (A) nasal epithelial cells (HNEpC) and (B) bronchial epithelial cells (NHBE). Data is expressed as the mean ± SEM; three independent experiments assayed in triplicates. Statistical significance # p < 0.01 compared to the non-stimulated control; *p < 0.05, **p < 0.01, ***p < 0.001 compared to stimulated control (+LPS). Control—non-stimulated cells, LPS—LPS-stimulated cells, B—budesonide tested at 50 μM, C—clarithromycin tested at 50 µM.

G. squarrosa Extract Modulates Cytokine Production and 65 NF-κb Concentration

Lipopolysaccharide (LPS) stimulation of human nasal and bronchial epithelial cells resulted in the production wide range of cytokines: TNF-α, IL-1β, IL-6 and IL-8 (leukocyte chemotactic factors). G. squarrosa extract as well as grindelic acid were tested at concentration range of 25–100 μg/ml, and 10–50 μM, respectively. IL-1β and TNF-α, called early-released proinflammatory cytokines, were significantly suppressed by G. squarrosa extract in both epithelial models (p < 0.001; Figures 3A–D). Budesonide, well known corticosteroid with strong anti-inflammatory activity, suppressed IL-1β and TNF-α production, similarly like extract tested at 50 μg/ml (p < 0.001). Additionally, G. squarrosa extract was more active than clarithromycin, which served as a second positive control (p < 0.05). The activity of grindelic acid was significant only in the highest concentration 50 µM (p < 0.05) in both epithelial models.

FIGURE 3.

FIGURE 3

Open in a new tab

Effects of G . squarrosa extract and tested compounds on chemo- and cytokines production by LPS-stimulated nasal and bronchial epithelial cells: TNF-α secretion by (A) nasal epithelial cells (HNEpC) and (B) bronchial epithelial cells (NHBE); IL-1β secretion by (C) nasal epithelial cells (HNEpC) and (D) bronchial epithelial cells (NHBE); IL-6 secretion by (E) nasal epithelial cells (HNEpC) and (F) bronchial epithelial cells (NHBE); IL-8 secretion by (G) nasal epithelial cells (HNEpC) and (H) bronchial epithelial cells (NHBE).

IL-6 and IL-8 were chosen for assessment as late-released proinflammatory cytokines. G. squarrosa extract at 25–100 μg/ml significantly inhibited IL-8 production in both epithelial models (p < 0.001) in dose dependent manner. The effect of G. squarrosa on IL-6 production was significant only up to 50 μg/ml (Figures 3E–H). The biological activity of budesonide was significant (p < 0.001) in both epithelial models. However, clarithromycin did not influence on IL-8 and IL-6 production.

Evaluation of p65 NF-κB concentration explains the molecular mechanism responsible for previously observed cytokine concentration changes. Our data show that G. squarrosa extract at the concentration range 25–100 μg/ml significantly decreased p65 production (p < 0.001) (Figures 4A,B). Similarly, budesonide tested at 50 µM significantly inhibited p65 production, and final effect was comparable to plant extract tested at 100 μg/ml.

FIGURE 4.

FIGURE 4

Open in a new tab

The influence of G . squarrosa extract and compounds on p65 NF-κB concentration after LPS stimulation of nasal epithelial cells (HNEpC) and (B) bronchial epithelial cells (NHBE).

Interestingly, decrease of p65 concentration was observed also for grindelic acid and clarithromycin, both tested at 50 µM.

G. squarrosa Extract Treatment Reduces Macrophage Adhesion to Epithelium

Stimulation with LPS also results in adhesive molecules expression changes (ICAM-1, VCAM-1 and E-selectin), these then direct the emigration of macrophages across the endothelial to epithelial cells. Mentioned adhesive molecules play a different roles depending on the cells where they are located. On the endothelial cells ICAM-1, VCAM-1 and E-selectin precisely coordinate migration, rolling and diapedesis of leukocytes, however, on the epithelial cells they strictly coordinate adhesion leukocytes to epithelium.

The biological effect of G. squarrosa treatment was significant only for ICAM-1 expression (Table 3). Comparing to LPS-stimulated control (100%) the plant extract tested at the highest concentration (100 μg/ml) decreased ICAM-1 concentration to 75.3 ± 3.4% in the nasal epithelium, and to 78.2 ± 5.3% in the bronchial epithelium. Similarly, budesonide, tested at 50 µM decreased ICAM-1 expression to 79.4 ± 4.9% and 80.5 ± 3.8%, respectively. Expression of VCAM-1 and E-selectin did not change after treatment.

TABLE 3.

Effects of G. squarrosa extract and tested compounds on the adhesive molecules expression (ICAM-1, VCAM-1 and E-selectin) located on the nasal and bronchial epithelial cells. Data is expressed as the mean ± SEM; three independent experiments assayed in triplicates. Statistical significance a p < 0.01 compared to the non-stimulated control; b p < 0.05, c p < 0.01, d p < 0.001 compared to stimulated control (+LPS).

ICAM-1 expression [%] VCAM-1 expression [%] E-selectin expression [%]
Nasal Bronchial Nasal Bronchial Nasal Bronchial
Control 34.2 ± 3.6 28.4 ± 1.3 26.4 ± 7.2 30.2 ± 5.5 24.1 ± 3.9 19.3 ± 6.2
Stimulation (+LPS) 100 ± 2.1 100 ± 4.5 100 ± 5.1 100 ± 3.9 100 ± 2.8 100 ± 5.9
G. squarrosa extract + LPS
 25 μg/ml 94.3 ± 5.9 99.3 ± 3.7 89.6 ± 5.3 95.2 ± 3.4 90.9 ± 6.1 97.7 ± 9.4
 50 μg/ml 88.3 ± 2.9 90.5 ± 4.2 94.2 ± 2.8 90.3 ± 6.1 94.2 ± 3.1 93.2 ± 1.8
 100 μg/ml 75.3 ± 3.4 b 78.2 ± 5.3 b 92.5 ± 6.1 88.4 ± 7.9 93.8 ± 4.1 96.2 ± 3.9
Grindelic acid + LPS
 10 µM 89.5 ± 6.9 90.5 ± 8.2 97.4 ± 5.3 98.8 ± 2.4 96.4 ± 2.5 99.3 ± 2.8
 20 µM 88.9 ± 9.8 92.1 ± 4.2 95.2 ± 4.6 97.2 ± 1.8 99.4 ± 3.7 93.2 ± 3.7
 50 µM 90.4 ± 2.7 91.6 ± 3.7 89.6 ± 4.6 93.2 ± 4.1 91.3 ± 9.2 89.3 ± 7.9
 Budesonide 50 µM 79.4 ± 4.9 b 80.5 ± 3.8 b 92.5 ± 9.1 90.3 ± 7.1 86.4 ± 6.9 89.5 ± 8.3
 Clarithromycin 50 µM 95.3 ± 3.9 92.8 ± 6.2 94.3 ± 5.7 96.3 ± 3.6 99.4 ± 1.8 91.4 ± 6.7
Open in a new tab
a

p < 0.01 vs. not stimulated cells;

b

p < 0.05 vs. LPS-stimulated cells;

c

p < 0.01 vs. LPS-stimulated cells;

d

p < 0.001 vs. LPS-stimulated cells.

Continuing, we evaluated influence of extract and compounds on the adhesion of macrophages to both epithelial models (Figure 5). As described in the Material and Methods epithelial cells were previously pre-incubated with extract or compounds, then stimulated with LPS and co-incubated with LPS-stimulated macrophages. Because bacterial infection lead to modulation of pro-inflammatory functions both respiratory epithelium as well as leukocytes, the stimulation with LPS of both models seems to be justified. The proposed cellular models reflect the cellular response to bacterial infection properly.

FIGURE 5.

FIGURE 5

Open in a new tab

The influence of G. squarrosa extract and compounds on adhesion of macrophages to nasal epithelial cells (HNEpC) and bronchial epithelial cells (NHBE).

It is worth to emphasize, that bacterial infection resulting very often with inflammation may lead to excessive activation macrophages. Macrophages are very sensitive for a pro-inflammatory cytokine presence in the bloodstream. Very low concentrations of TNF-α or IL-8 significantly stimulate their chemotaxis to damaged tissues. Because they response to recognized chemoattractant immediately (they play a critical role in nonspecific defense (innate immunity)). Thus, there is a risk of their uncontrolled migration and over-accumulation, what increases the need of pharmacological control their adhesion to epithelium.

Our observations, indicate that G. squarrosa extract tested at 50 and 100 μg/ml decreased adhesion of macrophages to nasal epithelium to 74.8 ± 6.7% and to 65.0 ± 8.4%, respectively (Figure 5A). Budesonide, widely used for a treatment of inflammation-related diseases, decreased adhesion to 55.7 ± 5.7%. Similar tendency we observed for the bronchial epithelial cells co-cultured with macrophages (Figure 5B). G. squarrosa extract affected the macrophage adhesion to bronchial epithelium much stronger than to nasal epithelium. Tested at concentrations 25, 50, and 100 μg/ml decreased the adhesion to 76.5 ± 9.1, 62.3 ± 7.7, and 56.8 ± 5.1%. Comparing the strong anti-inflammatory activity of budesonide (decreased adhesion of macrophages to bronchial cells to 46.3 ± 8.5%) with anti-inflammatory properties of tested G. squarrosa extract and its lack of cytotoxic properties (Supplementary Table S1) our findings proved competitiveness of phytotherapy.

G. squarrosa Extract and Grindelic Acid Modulate Pro- and Anti-inflammatory Functions of LPS-Stimulated Macrophages

The G. squarrosa extract (at 25–100 μg/ml) significantly upregulated IL-10 receptor expression. Similar effect was observed for grindelic acid tested at 50 µM (p < 0.05) (Table 4). The extract and grindelic acid significantly promote anti-inflammatory functions of macrophages through stimulation of TGF-β production (p < 0.001). G. squarrosa extract treatment also resulted in suppression of pro-inflammatory cytokines: TNF-α and IL-6 in dose dependent manner (p < 0.001 for all tested concentrations). Budesonide, well known anti-inflammatory drug capable of suppressing cytokine release, at 50 µM inhibited TNF-α and IL-6 to 45.4 and 56.5%, respectively. The activity of clarithromycin was evident but more modest. The tested extract, compounds and solvent (DMSO) were not toxic for mononuclear, as shown by assessing their influence on monocyte/macrophages membrane integrity at the tested concentrations (Supplementary Table S1).

TABLE 4.

Effects of G. squarrosa extract and tested compounds on pro- and anti-inflammatory functions of LPS-stimulated monocytes/macrophages: IL-10 receptor expression on the surface of stimulated macrophages; TGF-β secretion by stimulated macrophages [pg/mL]; IL-6 secretion by stimulated macrophages [%]; TNF-α secretion by stimulated macrophages [%]. Data is expressed as the mean ± SEM; three independent experiments assayed in triplicates. Statistical significance a p < 0.01 compared to the non-stimulated control; b p < 0.05, c p < 0.01, d p < 0.001 compared to stimulated control (+LPS).

Surface IL-10 receptor expression [%] TGF-β release [pg/mL] IL-6 release [%] TNF-α release [%]
Control 100.2 ± 21.6 33.7 ± 7.9 a 34.4 ± 4.2 24.3 ± 5.4
Stimulation (+LPS) 46.4 ± 15.5 a 8.5 ± 4.8 a 100.0 ± 2.1 a 100.4 ± 3.3 a
G. squarrosa extract + LPS
 25 μg/ml 257.4 ± 61.8 d 37.5 ± 2.1 64.3 ± 6.2 d 58.5 ± 2.5 d
 50 μg/ml 476.6 ± 62.4 d 43.6 ± 4.8 60.2 ± 4.4 d 55.3 ± 3.8 d
 100 μg/ml 904.3 ± 96.4 d 58.4 ± 4.4 c 52.5 ± 2.2 d 45.2 ± 2.8 d
Grindelic acid + LPS
 10 µM 13.8 ± 3.6 n.d 87.9 ± 4.7 90.4 ± 3.3
 20 µM 16.5 ± 5.5 n.d 84.4 ± 8.2 85.3 ± 2.7
 50 µM 18.1 ± 6.2 35.3 ± 9.8 74.3 ± 3.5 c 76.6 ± 0.9
100 μg/ml
 Budesonide 50 µM 50.0 ± 5.6 40.3 ± 2.1 56.4 ± 3.8 d 65.9 ± 1.6 d
 Clarithromycin 50 µM 64.4 ± 4.7 n.d 68.4 ± 6.6 c 78.6 ± 2.1 b
Open in a new tab

n.d., not detectable.

a

p < 0.01 vs. not stimulated cells;

b

p < 0.05 vs. LPS-stimulated cells;

c

p < 0.01 vs. LPS-stimulated cells;

d

p < 0.001 vs. LPS-stimulated cells.

Discussion

Aerial parts of Grindelia were traditionally used to treat cold-related diseases. Importantly, as liquid extracts and syrups they are still widely distributed at Polish and German markets (Gierlikowska et al., 2020a). The commercial spread of extract for cough and bronchitis treatment increased the need of understanding the biological mechanism of action.

Although the phytochemical composition of Grindelia squarrosa is well-known (Veres et al., 2014; Nowak et al., 2019) the biological activity is still not explained. In our previous study we documented anti-inflammatory properties of G. squarrosa extract tested on human neutrophilic model (Gierlikowska et al., 2020a). Now, we expand the study and present how G. squarrosa regulates pro-inflammatory functions of respiratory epithelium and macrophages, and how modulates their mutual interactions. Our main findings explain how G. squarrosa extract modulates molecular mechanisms involved in epithelial response to LPS stimulation, and how it regulates migration and adhesion of macrophages to respiratory epithelium.

The acute episode of a cold starts with virus infection and may be accompanied by bacterial superinfection. Grindelia species were shown to exert antimicrobial activity, especially against gram negative E. coli (Hassan et al., 2014). According to Hassan et al. (Hassan et al., 2014) the extract of G. squarrosa flowers showed inhibition diameters in excess of 19.3 mm of A. caviae, M. luteus and P. alvei. Similar results were obtained by Jacobs et al. (Jacobs et al., 2010). Using different extracts solvents (CCl4 and 1-BuOH) they confirmed anti-microbial properties of G. squarrosa: CCL4-extract inhibited E. coli, S. aureus and C. albicans growth, whereas 1-BuOH-extract inhibited S. aureus, P. aeruginosa and K. pneumoniae (Jacobs et al., 2010). In the present study we tested anti-microbial activity of 60%-EtOH extract, and we did not observe any anti-microbial activity. Only clarithromycin, used as positive control, significantly inhibited growth of selected gram positive: S. aureus and S. pneumoniae (growth inhibition zone, GIZ: 30–34 mm). The water-ethanol extraction, as we performed in present study, reflects the way in which market preparations are obtained. Comparing our results with experiments performed by Hassan (Hassan et al., 2014) and Jacobs (Jacobs et al., 2010) we could hypothesize that different solvents may determine differences in the phytochemical composition and affect on their anti-microbial properties.

The pathogenic infection results in development of full-symptomatic inflammation (Roxas and Jurenka, 2007). Bacterial infection starts with interaction of pathogens with Toll-like receptors located on epithelial cells. To response to gram negative bacteria/LPS, TLR-4 expression increases. To our knowledge, there is no data showing the influence of G. squarrosa extract and/or grindelic acid on TLR-4 expression. Using two cellular models (nasal and bronchial epithelium) we observed significant decrease of TLR-4 expression after treatment. Modest activity of grindelic acid may suggest, that anti-inflammatory activity of the extract is not determined be grindelic acid (being the major diterpene), but it is a synergistic effect of all compounds present in the extract.

When nasal and bronchial epithelial cells are exposed to bacterial infection, they secrete a wide spectrum of pro-inflammatory cytokines in a precisely defined sequence (Broekman et al., 2016). At the beginning of infection, low amounts of “early-inflammatory cytokines”—IL-1β and TNF-α are released. Both cytokines intensify production of the “late-inflammatory cytokines”—IL-6 and IL-8 by the respiratory epithelial cells (Broekman et al., 2016), and stimulate chemotaxis of macrophages. It is known that cytokines promote adequate immune response, but prolonged cytokines production by stimulated respiratory epithelial cells may exacerbate inflammation. The side effects arise from excessive macrophage chemotaxis and prolonged stimulation of their pro-inflammatory functions.

Our next finding indicates that G. squarrosa extract significantly inhibited IL-1β, TNF-α, IL-6, and IL-8 production by epithelial cells via p65 NF-κB suppression. Our observations are coincident with observations performed by La et al. (La et al., 2010). La and al. presented anti-inflammatory properties of Grindelia robusta Nutt. tested on monocyte-derived macrophages (U937, human monoblastic leukemia cell line) (La et al., 2010). The authors showed that G. robusta extract tested at concentration range 25–100 μg/ml inhibited dose-dependently the secretion of IL-6, MCP-1 and, to a lesser extent, PGE2 and TNF-α. Such inhibition was also observed for MMP-1, -3, -7, -8, -9, and -13 production. The ability of G. robusta extract to reduce the LPS-induced secretion of inflammatory mediators and MMPs was associated with a reduction of nuclear factor-kappa B (NF-kB) p65 activation (La et al., 2010). Despite differences in chemical composition of G. squarrosa and G. robusta it is worth emphasizing that both extracts present ability to suppression of pro-inflammatory cytokine production (La et al., 2010; Gierlikowska et al., 2020a).

Secretion of proinflammatory chemokines and cytokines (interleukins IL-8, IL-1β and TNF-α) induces inflammatory and immune responses (Liu et al., 2016). In respiratory epithelium these effects are associated with the activation of mitogen-activated protein kinases (MAPKs), i.e., p38 kinase, p42/44 extracellular signal-regulated kinase (ERK), and c-Jun NH2-terminal kinases (JNKs), and are regulated by two major transcription factors families, i.e., NF-κB and AP-1 (Liu et al., 2016; Yang et al., 2017; Zhang et al., 2018). In the available literature there is no data regarding the influence of G. squarrosa extract and grindelic acid on MAPK pathway and AP-1. However, based on results obtained for p65 NF-κB we could hypothesize that G. squarrosa may modulate p65 NF-κB via inhibition of MAPKs activity. The activation of AP-1 is also mediated by MAPKs thus verification of mentioned hypothesis may highlight new targets for a cold-related diseases treatment.

Based on our experiments performed on a two independent epithelial models (nasal and bronchial epithelium), we can speculate that G. squarrosa, through strong inhibition of chemoattractant production (IL-1β, TNF-α, IL-6, and IL-8), may potentially limit activation, and migration macrophages to damaged epithelial cells. However, macrophages are very sensitive to cytokines released to bloodstream, thus even small amounts of secreted cytokines may activate adequate immune response.

The migration of macrophages to damaged epithelium is strictly dependent on TNF-α, IL-β, and IL-8 concentration in the bloodstream (Rosseau et al., 2000). Released by damaged epithelium pro-inflammatory cytokines increase expression of VCAM-1, E-selectin, and ICAM-1 (Turner et al., 2011). On the contrary to VCAM-1 and E-selectin, ICAM-1 appears on the epithelium later and is located only at the site of inflammation.

In our study, we tested influence of G. squarrosa on the expression of mentioned above adhesive molecules, however, we did not observe influence of extract on VCAM-1 and E-selectin expression. At the highest concentration (100 μg/ml) G. squarrosa extract slightly inhibited only ICAM-1 expression. The comparable effect was noticed for budesonide tested at 50 µM. The reduction of ICAM-1 expression may be related with inhibition of cytokine production. As therapeutic target for ICAM-1 suppression were identified IL-8 and TNF-α (Kwon et al., 2011; Kim et al., 2013; Gao et al., 2018). Why extract modulates only adhesion molecule responsible for attachment of leukocytes to epithelium, also remains to be elucidated.

Although, G. squarrosa treatment did not affect on epithelial adhesive molecules expression directly, it suppressed the macrophage adhesion to epithelium. At concentration above 50 μg/mL G squarrosa significantly inhibited the adhesion of macrophages to both epithelial models. The lowest tested concentration (25 μg/ml) decreased adhesion of macrophages only to bronchial epithelium.

The differences between an affect of G. squarrosa treatment on percentage of adhered of macrophages to nasal and bronchial epithelium may be partially explained by epithelial cells anatomical location, predispose to infection/damage and ability to regeneration. The nasal cavity is constantly inhabited by pathogens and is more exposed to mechanical damage (Man et al., 2017). The lower respiratory tract is sterile, thus bronchial epithelial cells must have developed mechanisms that protect not only against pathogens, but also against excessive accumulation of phagocytes. Resseau et al. (Rosseau et al., 2000) explained the stricted regulation of emigration into the alveolar compartment by the difficulties with successful clearance of macrophages from the lung parenchyma. Thus, the observed stronger inhibition of macrophage adhesion to bronchial epithelium then nasal epithelium may be a result of an additive effect of G. squarrosa treatment and physiological response of bronchial cell to interactions with macrophages.

At the end, we confirmed that G. squarrosa extract stimulate anti-inflammatory functions of macrophages by increase of TGF-β production and IL-10 expression what accelerates the removal of pathogens and damaged tissues (Aggarwal et al., 2014). G. squarrosa also reduced concentration of pro-inflammatory cytokines (IL-6 and TNF-α) released by macrophages, successfully reducing inflammation.

In our opinion the biological activity of grindelic acid was a type of cell-dependent. At the highest tested concentration (50 µM) grindelic acid selectively modulated respiratory epithelium functions (TLR-4 expression, cytokine production and p65 NF-κB concentration). Interestingly, grindelic acid did not affect adhesive molecules expression and pro-inflammatory functions of macrophages. According to Leiva-Juárez et al. (Leiva-Juárez et al., 2018) the highly plastic epithelial barrier responds to detected threats via modulation of drug accumulation, paracellular flux, intercellular communications, mucin production, and periciliary fluid composition. Epithelial stimulation induces production of cytokines that recruit and sculpt leukocyte-mediated responses, and promotes epithelial generation of antimicrobial effector molecules that are directly microbicidal. Thus epithelium can alternately enhance tolerance to pathogens, preventing tissue damage through induced inhibitory signals and through potential accumulation of compound may attenuate of injurious leukocyte responses (Leiva-Juárez et al., 2018).

Summarizing, our results explain how G. squarrosa modulates pro-inflammatory functions of nasal, bronchial epithelium and macrophages, and their mutual interactions (Figure 6). We confirmed anti-inflammatory properties of G. squarrosa and influence on modulation of leukocyte adhesion to nasal and bronchial epithelial cells. The obtained results allow to better understand the therapeutic efficacy of G. squarrosa raw material.

FIGURE 6.

FIGURE 6

Open in a new tab

The summary of influence of G. squarrosa extract on the proinflammatory functions of respiratory epithelium.

Conclusion

The present study justified the traditional use of Grindelia squarrosa aerial parts for treatment of cold-related diseases. The wide-spread use of G. squarrosa in the traditional medicine and effectiveness during cold-related diseases treatment may be explained by modulation of pro-inflammatory functions respiratory epithelium and macrophages.

The observed suppression of inflammation was a result of “cascade suppressed pro-inflammatory cell response.” The G. squarrosa suppressed TLR-4 expression, decreased p65 NF-κB concentration and resulted in suppression of TNF-α, IL-1β, IL-6, and IL-8 production. Moreover, we noticed stimulation of anti-inflammatory functions of macrophages and inhibition of their adhesion to nasal and bronchial epithelium. Our observations suggest the high therapeutic potential of G. squarrosa extract during symptomatic treatment of cold-related diseases.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics Statement

The studies involving human participants were reviewed and approved by Committee on Bioethics at the Medical University of Warsaw. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

BG designed the study and supervised the work. BG and AK selected plant material and obtained financial support (FW25/PM3/18). DK and AK performed phytochemical analysis. BG, AF, WG, and JS planned and performed the biological experiments and carried out data analysis. BG wrote the manuscript. UD critically reviewed the manuscript.

Funding

The study was financed by Medical University of Warsaw, Poland—program: Young Researcher Grant (No. FW25/PM3/18).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.534111/full#supplementary-material.

Click here for additional data file. (466KB, docx)

References

  1. Aggarwal N. R., Tsushima K., Eto Y., Tripathi A., Mandke P., Mock J. R., et al. (2014). Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation. J. Immunol. 192 (9), 4453–4464. 10.4049/jimmunol.1400146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bandi N., Kompella U. B. (2001). Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur. J. Pharmacol. 425 (2), 109–116. 10.1016/s0014-2999(01)01192-x [DOI] [PubMed] [Google Scholar]
  3. Broekman W., Amatngalim G. D., de Mooij-Eijk Y., Oostendorp J., Roelofs H., Taube C., et al. (2016). TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor. Respir. Res. 17, 3 10.1186/s12931-015-0316-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Capasso F., Gaginella T. S., Grandolini G., Izzo A. A. (2003). Phytotherapy: a quick reference to herbal medicine. Berlin, Germany: Springer Science and Business Media. [Google Scholar]
  5. Dudek M. K., Michalak B., Woźniak M., Czerwińska M. E., Filipek A., Granica S., et al. (2017). Hydroxycinnamoyl derivatives and secoiridoid glycoside derivatives from Syringa vulgaris flowers and their effects on the pro-inflammatory responses of human neutrophils. Fitoterapia. 121, 194–205. 10.1016/j.fitote.2017.07.008 [DOI] [PubMed] [Google Scholar]
  6. Efferth T., Koch E. (2011). Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets 12 (1), 122–132. 10.2174/138945011793591626 [DOI] [PubMed] [Google Scholar]
  7. Erwin A. L., Smith A. L. (2007). Nontypeable Haemophilus influenzae: understanding virulence and commensal behavior. Trends Microbiol. 15 (8), 355–362. 10.1016/j.tim.2007.06.004 [DOI] [PubMed] [Google Scholar]
  8. Ferreres F., Grosso C., Gil-Izquierdo A., Valentão P., Azevedo C., Andrade P. B. (2014). HPLC-DAD-ESI/MS(n) analysis of phenolic compounds for quality control of Grindelia robusta Nutt. and bioactivities. J. Pharmaceut. Biomed. Anal. 94, 163–172. 10.1016/j.jpba.2014.01.046 [DOI] [PubMed] [Google Scholar]
  9. Gao H., Zhang Q., Chen J., Cooper D. K. C., Hara H., Chen P., et al. (2018). Porcine IL-6, IL-1β, and TNF-α regulate the expression of pro-inflammatory-related genes and tissue factor in human umbilical vein endothelial cells. Xenotransplantation 25 (5), e12408 10.1111/xen.12408 [DOI] [PubMed] [Google Scholar]
  10. Gierlikowska B., Gierlikowski W., Bekier K., Skalicka-Woźniak K., Czerwińska M. E., Kiss A. K. (2020a). Inula helenium and Grindelia squarrosa as a source of compounds with anti-inflammatory activity in human neutrophils and cultured human respiratory epithelium. J. Ethnopharmacol. 249, 112311 10.1016/j.jep.2019.112311 [DOI] [PubMed] [Google Scholar]
  11. Gierlikowska B., Gierlikowski W., Demkow U. (2020b). Alantolactone enhances the phagocytic properties of human macrophages and modulates their proinflammatory functions. Front. Pharmacol. 11, 1339 10.3389/fphar.2020.01339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goetz P. (2005). Plantes médicinales d’Amérique du Nord: apport à la phytothérapie française du traitement des affections des voies respiratoires. Phytothérapie. 3 (1), 19–27. 10.1007/s10298-005-0060-7 [DOI] [Google Scholar]
  13. Hassan H. M., Jiang Z.-H., Asmussen C., McDonald E., Qin W. (2014). Antibacterial activity of northern Ontario medicinal plant extracts. Can. J. Plant Sci. 94 (2), 417–424. 10.4141/cjps2013-258 [DOI] [Google Scholar]
  14. Jacobs J., Dixson J., Gabel M., Bergmann D., DeCory J., Geffre C. (2010). Antimicrobial screening on fourteen traditional American Indian medicinal plants. Proc. S. D. Acad. Sci. 89, 85–93. [Google Scholar]
  15. Johnson L. N. (1887). Grindelia squarrosa. Science 10 (242), 152 10.1126/science.ns-10.242.152-a [DOI] [PubMed] [Google Scholar]
  16. Kalktenbach G., Schimmer O. (1991). Volatile constituents of the herbs of grindelia robusta and grindelia squarrosa. Planta Med. 57 (S2), A82 10.1080/10412905.1993.9698182 [DOI] [Google Scholar]
  17. Kim K. H., Park J. K., Choi Y. W., Kim Y. H., Lee E. N., Lee J. R., et al. (2013). Hexane extract of aged black garlic reduces cell proliferation and attenuates the expression of ICAM-1 and VCAM‑1 in TNF-α-activated human endometrial stromal cells. Int. J. Mol. Med. 32 (1), 67–78. 10.3892/ijmm.2013.1362 [DOI] [PubMed] [Google Scholar]
  18. Klugman K. P., Feldman C. (2001). Streptococcus pneumoniae respiratory tract infections. Curr. Opin. Infect. Dis. 14 (2), 173–179. 10.1097/00001432-200104000-00011 [DOI] [PubMed] [Google Scholar]
  19. Kwon D. J., Bae Y. S., Ju S. M., Goh A. R., Choi S. Y., Park J. (2011). Casuarinin suppresses TNF-α-induced ICAM-1 expression via blockade of NF-κB activation in HaCaT cells. Biochem. Biophys. Res. Commun. 409 (4), 780–785. 10.1016/j.bbrc.2011.05.088 [DOI] [PubMed] [Google Scholar]
  20. La V. D., Lazzarin F., Ricci D., Fraternale D., Genovese S., Epifano F., et al. (2010). Active principles of Grindelia robusta exert antiinflammatory properties in a macrophage model. Phytother Res. 24 (11), 1687–1692. 10.1002/ptr.3195 [DOI] [PubMed] [Google Scholar]
  21. Leiva-Juárez M. M., Kolls J. K., Evans S. E. (2018). Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense. Mucosal Immunol. 11 (1), 21–34. 10.1038/mi.2017.71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Liu Z., Wu H., Jiang K., Wang Y., Zhang W., Chu Q., et al. (2016). MAPK-mediated YAP activation controls mechanical-tension-induced pulmonary alveolar regeneration. Cell Rep. 16 (7), 1810–1819. 10.1016/j.celrep.2016.07.020 [DOI] [PubMed] [Google Scholar]
  23. Mahmoud A. A., Ahmed A. A., Tanaka T., Iinuma M. (2000). Diterpenoid acids from Grindelia nana. J. Nat. Prod. 63 (3), 378–380. 10.1021/np9904105 [DOI] [PubMed] [Google Scholar]
  24. Man W. H., de Steenhuijsen Piters W. A., Bogaert D. (2017). The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat. Rev. Microbiol. 15 (5), 259–270. 10.1038/nrmicro.2017.14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Martin T. R., Mathison J. C., Tobias P. S., Letúrcq D. J., Moriarty A. M., Maunder R. J., et al. (1992). Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J. Clin. Invest. 90 (6), 2209–2219. 10.1172/jci116106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Martin T. R. (2000). Recognition of bacterial endotoxin in the lungs. Am. J. Respir. Cell Mol. Biol. 23 (2), 128–132. 10.1165/ajrcmb.23.2.f189 [DOI] [PubMed] [Google Scholar]
  27. McFarlane J. (2017). Fractionation-assisted NMR-based metabolomics of Grindelia squarrosa. Available at: https://core.ac.uk/download/pdf/84872767.pdf [Google Scholar]
  28. Michalak B., Filipek A., Chomicki P., Pyza M., Woźniak M., Żyżyńska-Granica B., et al. (2018). Lignans from forsythia x intermedia leaves and flowers attenuate the pro-inflammatory function of leukocytes and their interaction with endothelial cells. Front. Pharmacol. 9, 401 10.3389/fphar.2018.00401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mizgerd J. P. (2008). Acute lower respiratory tract infection. N. Engl. J. Med. 358 (7), 716–727. 10.1056/NEJMra074111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nowak S., Lisiecki P., Tomaszczak-Nowak A., Grudzińska E., Olszewska M. A., Kicel A. (2019). Chemical composition and antimicrobial activity of the essential oils from flowers and leaves of Grindelia integrifolia DC. Nat. Prod. Res. 33 (10), 1535–1540. 10.1080/14786419.2017.1423302 [DOI] [PubMed] [Google Scholar]
  31. Nowak S., Rychlińska I. (2012). Phenolic acids in the flowers and leaves of grindelia robusta Nutt. And grindelia squarrosa dun. (Asteraceae). Acta Pol. Pharm. 69 (4), 693–698. [PubMed] [Google Scholar]
  32. Puneet P., Moochhala S., Bhatia M. (2005). Chemokines in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell Mol. Physiol. 288 (1), L3–L15. 10.1152/ajplung.00405.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Reta G. F., Chiaramello A. I., García C., León L. G., Martín V. S., Padrón J. M., et al. (2013). Derivatives of grindelic acid: from a non-active natural diterpene to synthetic antitumor derivatives. Eur. J. Med. Chem. 67, 28–38. 10.1016/j.ejmech.2013.06.013 [DOI] [PubMed] [Google Scholar]
  34. Rosseau S., Selhorst J., Wiechmann K., Leissner K., Maus U., Mayer K., et al. (2000). Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J. Immunol. 164 (1), 427–435. 10.4049/jimmunol.164.1.427 [DOI] [PubMed] [Google Scholar]
  35. Roxas M., Jurenka J. (2007). Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Alternative Med. Rev. 12 (1), 25–48. [PubMed] [Google Scholar]
  36. Spiegler V., Gierlikowska B., Saenger T., Addotey J. N., Sendker J., Jose J., et al. (2020). Root extracts from ononis spinosa inhibit IL-8 release via interactions with toll-like receptor 4 and lipopolysaccharide. Front. Pharmacol. 11, 889 10.3389/fphar.2020.00889 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Strzelecka H. (2000). Encyklopedia zielarstwa i ziołolecznictwa. Warsaw, Poland: Naukowe PWN. [Google Scholar]
  38. Timmermann B. N., Hoffmann J. J., Jolad S. D., Schram K. H. (1985). Grindelane diterpenoids from grindelia squarrosa and. G. camporum . Phytochemistry 24 (5), 1031–1034. 10.1016/S0031-9422(00)83176-3 [DOI] [Google Scholar]
  39. Turner N. A., Das A., O'Regan D. J., Ball S. G., Porter K. E. (2011). Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation. Int. J. Biochem. Cell Biol. 43 (10), 1450–1458. 10.1016/j.biocel.2011.06.008 [DOI] [PubMed] [Google Scholar]
  40. Veres K., Roza O., Laczkó-Zöld E., Hohmann J. (2014). Chemical composition of essential oils of Grindelia squarrosa and G. hirsutula . Nat Prod Commun. 9 (4), 573–574. 10.1177/1934578X1400900438 [DOI] [PubMed] [Google Scholar]
  41. Watts J. (2008). Clinical and laboratory standards institute performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: approved standard. Annapolis Junction, MD: National Committee for Clinical Laboratory Standards. [Google Scholar]
  42. Yang H. W., Lee S. A., Shin J. M., Park I. H., Lee H. M. (2017). Glucocorticoids ameliorate TGF-β1-mediated epithelial-to-mesenchymal transition of airway epithelium through MAPK and Snail/Slug signaling pathways. Sci. Rep. 7 (1), 3486 10.1038/s41598-017-02358-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Zhang X., Wang T., Yuan Z. C., Dai L. Q., Zeng N., Wang H., et al. (2018). Mitochondrial peptides cause proinflammatory responses in the alveolar epithelium via FPR-1, MAPKs, and AKT: a potential mechanism involved in acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 315 (5), L775-l786. 10.1152/ajplung.00466.2017 [DOI] [PubMed] [Google Scholar]
  44. Zusso M., Lunardi V., Franceschini D., Pagetta A., Lo R., Stifani S., et al. (2019). Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. J. Neuroinflammation 16 (1), 148 10.1186/s12974-019-1538-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (466KB, docx)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES